254 related articles for article (PubMed ID: 23256481)
1. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
6. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
8. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
[TBL] [Abstract][Full Text] [Related]
12. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
[TBL] [Abstract][Full Text] [Related]
16. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
17. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
19. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.
Kim YJ; Lee WJ; Woo SM; Kim TH; Han SS; Kim BH; Moon SH; Kim SS; Koh YH; Park SJ; Kim JY; Kim DY; Park JW
Radiat Oncol; 2013 Jul; 8():160. PubMed ID: 23822606
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
